Search results for: Multi-Indication Medicines
Filter search results
Seminar Updates Project on Time Lags in Medical Research
8 October 2013
…at medicines (amlodipine and olanzapine), screening (for abdominal aortic aneurysms), public health (smoking reduction), psychosocial interventions (cognitive behavioural therapy for depression and for schizophrenia), and service reorganisations (early intervention to…
Critique of Research Proposing to Lower NICE’s Cost-per-QALY Threshold to £12,936
2 December 2013
…quality-adjusted life-year (QALY). Therefore, they conclude, NICE should not approve medicines with a cost-per-QALY greater than this threshold. The critique by OHE’s Barnsley et al accepts the premise that NICE’s…
Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015
20 January 2015
…in the OHE research paper with the same title [OHE Research paper 14/02]. This presentation was part of the “Medicines Knowledge Base” series of lunchtime briefing seminars organised by…
Benefiting Sooner from Medical Research
3 February 2015
…sources. The technologies in the seven case studies range from medicines to public health measures to behavioural therapy to a service reorganisation aimed at early intervention. Overall we found…
OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
24 February 2015
…life year (QALY) in the English NHS in 2008/09. NICE currently uses a cost per QALY threshold of £20,000 to £30,000 – and so recommends many medicines and other…
OHE Briefing on Incentives to Follow Best Practice in Health Care
27 February 2015
…medicines or other health technologies. These incentives include monetary and non-monetary rewards. In the first section of the Briefing, the authors report the results of a review of empirical…
5 Things You Should Do with EQ-5D Data
29 January 2016
…‘utilities’) used in the calculation of QALYs (quality adjusted life years), EQ-5D has become the cornerstone of health technology appraisal (HTA), affecting important decisions about access to new medicines. But…
What Drives Variations in Relative Effectiveness Across Countries?
31 May 2016
…for exploring the use of a health production function approach to better understand the impact of new medicines and devices for improvements in health outcomes. Moreover, the health production function…
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
…analysis broadens the use of the term beyond predicting response to specific medicines. For the Joint OHE/EPEMED press rel ease The White Paper: The Value of Knowing and Knowing the…